Loading
Preparing stock search
Loading the search box, recent screening context, and the surrounding editorial guidance.
Help keep us running — this site is free to use and we cover the running costs ourselves. We're open to sponsors and advertising to keep it online. Get in touch.
Heads up — we're updating the site with more recent financial data over the coming days. Thanks for being patient with us.
Loading
Loading the search box, recent screening context, and the surrounding editorial guidance.
Company report
Review the methodology status, formula details, and supporting context for TVTX.
Methodology
AAOIFI
DJIM
S&P Shariah
Company
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Debt ratio
Formula
Total Interest-Bearing Debt / Market Capitalization (or Avg for AAOIFI/DJIM)
Thresholds
Cash ratio
Formula
(Cash + Interest-Bearing Securities) / Market Capitalization
Thresholds
Analysis
Haram revenue
Formula
Impermissible Revenue / Total Revenue
Thresholds
Methodology